文献速递骨质疏松与钙磷/甲状旁腺

rhPTH(1-84)治疗8年持续改善甲状旁腺功能减退症患者生活质量

Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

结果显示治疗显著改善SF-36多个维度,心理组分改善持续8年,躯体组分改善持续6年,基线评分较低及传统治疗需求减少者获益更明显。

要点

  • rhPTH(1-84)治疗8年持续改善甲状旁腺功能减退症患者SF-36多个维度评分。
  • 基线SF-36评分较低者及钙剂/骨化三醇需求减少者生活质量改善更显著。
  • 基线MCS<238和PCS<245可分别预测90%和100%患者获得长期改善。

核心结论

  • rhPTH(1-84)可长期改善甲状旁腺功能减退症患者的健康相关生活质量,基线SF-36受损及传统治疗需求大幅减少者获益最明显。

主要发现

  • rhPTH治疗使SF-36八个维度中的五个(活力、社会功能、心理健康、躯体疼痛、一般健康)大幅改善,其中社会功能、心理健康、躯体疼痛三个维度不再低于参考人群。
  • 心理组分总结评分改善持续8年,躯体组分总结评分改善持续6年。
  • 基线生活质量评分较低与更大改善相关;基线MCS<238和PCS<245分别预测90%和100%的患者获得长期改善。
  • 钙剂补充减少的患者MCS和PCS改善大于补充未同等减少者;骨化三醇剂量减少及病程较短者PCS改善更大。

关键数值与推荐

  • 基线MCS<238预测90%患者长期改善,基线PCS<245预测100%患者长期改善。
  • SF-36五个维度(活力、社会功能、心理健康、躯体疼痛、一般健康)显著改善,其中三个维度(社会功能、心理健康、躯体疼痛)不再低于参考人群。

临床怎么用

  • 对传统钙剂和维生素D治疗下生活质量仍受损的甲状旁腺功能减退症患者,可考虑rhPTH(1-84)长期治疗。
  • 基线SF-36评分较低及传统治疗需求可大幅减少的患者可能从rhPTH(1-84)治疗中获益更多。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Calcium and vitamin D treatment does not improve reduced quality of life (QOL) in hypoparathyroidism. Recombinant human (rh) PTH(1-84) therapy improves QOL metrics for up to 5 years. Data on QOL beyond this time point are not available. OBJECTIVES: To evaluate the effects of 8 years of rhPTH(1-84) therapy on QOL and factors associated with long-term benefit. DESIGN: Prospective, open-label trial. SETTING: Referral center. PATIENTS: Twenty patients with hypoparathyoidism. MAIN OUTCOME MEASURES: RAND 36-Item Short Form Health Survey (SF-36). RESULTS: rhPTH therapy led to substantial improvement in five of the eight SF-36 domains [vitality, social functioning (SF), mental health (MH), bodily pain (BP) and general health] and three of these domains (SF, MH, BP) were no longer lower than the reference population. The improvement in the mental component summary (MCS) score was sustained through 8 years, while the physical component summary (PCS) score improved through 6 years. A lower baseline QOL score was associated with greater improvement. A threshold value <238 (MCS) and <245 (PCS) predicted long-term improvement in 90% and 100% of the cohort, respectively. In patients whose calcium supplementation was reduced, MCS and PCS scores improved more than those whose supplementation did not decline to the same extent. Improvement in PCS was greater in patients whose calcitriol dosage was reduced and duration of disease was shorter. CONCLUSIONS: rhPTH(1-84) improves long-term well-being in hypoparathyroidism. The improvements are most prominent in those with impaired SF-36 at baseline and those whose requirements for conventional therapy decreased substantially.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Tabacco G, Tay YD, Cusano NE, et al. Quality of Life in Hypoparathyroidism Improves With rhPTH(1-84) Throughout 8 Years of Therapy. J Clin Endocrinol Metab. 2019. PMID: 30776291. doi:10.1210/jc.2018-02430

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。